Evidence map›Paper›PMID 35486292›Full record

Trial reportMolecular imaging and biology2022

FDG PET/CT and Dosimetric Studies of

Ayca Løndalen, Johan Blakkisrud, Mona-Elisabeth Revheim, Jostein Dahle, Arne Kolstad, Caroline Stokke

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Molecular imaging and biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ayca LøndalenDivision of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway. ayca.londalen@getmail.no.
Johan BlakkisrudDivision of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Mona-Elisabeth RevheimDivision of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Jostein DahleNordic Nanovector ASA, Oslo, Norway.
Arne KolstadDepartment of Oncology, Oslo University Hospital, Radiumhospital, Oslo, Norway.
Caroline StokkeDivision of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Oslo University Hospital · NOUniversity of Oslo · NONordic Nanovector (Norway) · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose[ PROCEDURES: Fifteen patients with different pre-dosing (non-radioactive lilotomab) regimens were included and the cohort was divided into low and high non-radioactive lilotomab pre-dosing groups for some of the analyses.

resultsSignificant decreases in tMTV and tTLG were observed at 3 months for patients receiving tTAD ≥ 200 cGy compared to patients receiving tTAD < 200 cGy (p = .03 for both). All non-responders had tTAD < 200 cGy. Large variations in tTAD were observed in responders. Reduction in

conclusiontTAD of ≥ 200 cGy may prove valuable to ensure clinical response, but further studies are needed to confirm this in a larger patient population. Furthermore, this work indicates that higher baseline tumor burden (up to 585 cm

Indexed as

Antineoplastic AgentsImmunoconjugatesLymphoma, Non-HodgkinAntibodies, MonoclonalFluorodeoxyglucose F18GlucoseHumansPositron Emission Tomography Computed Tomography(177)Lu-lilotomab satetraxetanAntibodies, MonoclonalAntineoplastic AgentsFluorodeoxyglucose F18GlucoseImmunoconjugatesFDG PET/CTIndolent non-Hodgkin lymphomaRadioimmunotherapySPECT/CTTumor absorbed dose

Identifiers

PMID35486292
PMCPMC9581842
OpenAlexW4225123234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.